NASDAQ:ANEB Anebulo Pharmaceuticals Q4 2025 Earnings Report $2.49 +0.03 (+1.22%) Closing price 09/16/2025 04:00 PM EasternExtended Trading$2.43 -0.06 (-2.41%) As of 05:12 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Anebulo Pharmaceuticals EPS ResultsActual EPSN/AConsensus EPS -$0.05Beat/MissN/AOne Year Ago EPSN/AAnebulo Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAnebulo Pharmaceuticals Announcement DetailsQuarterQ4 2025Date9/24/2025TimeBefore Market OpensConference Call DateMonday, September 22, 2025Conference Call Time4:00PM ETConference Call ResourcesEarnings HistoryCompany Profile Anebulo Pharmaceuticals Earnings HeadlinesAnebulo Pharmaceuticals provides update on going private transactionSeptember 12, 2025 | msn.comAnebulo Pharmaceuticals Announces Update on Going Private Transaction and Strategic AlternativesSeptember 12, 2025 | businesswire.comAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking and savings account… With this better, more technologically advanced dollar. President Trump himself called it a "big innovation"… And said that this new form of currency represents "American brilliance at its best." | Brownstone Research (Ad)Cannabis Use Disorder (CUD) Pipeline Market Research Report 2025 Featuring Aelis Farma, Anebulo Pharmaceuticals, and IndiviorJuly 25, 2025 | finance.yahoo.comMaxim Group Downgrades Anebulo Pharmaceuticals (ANEB)July 25, 2025 | msn.comAnebulo Pharmaceuticals stock soars after approving plan to go privateJuly 23, 2025 | investing.comSee More Anebulo Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Anebulo Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Anebulo Pharmaceuticals and other key companies, straight to your email. Email Address About Anebulo PharmaceuticalsAnebulo Pharmaceuticals (NASDAQ:ANEB) (NASDAQ:ANEB) is a clinical‐stage biopharmaceutical company focused on the development of intranasal therapies for the acute treatment of migraine. Its lead product candidate, ANEB-001, is an intranasal formulation of dihydroergotamine mesylate designed to provide rapid relief from migraine attacks while reducing common gastrointestinal side effects associated with oral treatments. The company is advancing ANEB-001 through pivotal trials in the United States and plans to submit a new drug application to the U.S. Food and Drug Administration upon completion of these studies. Anebulo has established manufacturing and distribution strategies to support future commercialization, aiming to deliver a differentiated option for patients who require fast-acting, non-oral migraine relief. Founded in 2019 and headquartered in Campbell, California, Anebulo Pharmaceuticals brings together a team of industry veterans in drug delivery and neurology. By leveraging proprietary intranasal delivery technology, the company seeks to address unmet needs in migraine care and expand its development pipeline in related therapeutic areas.View Anebulo Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Wall Street Eyes +30% Upside in Synopsys After Huge Earnings FallRH Stock Slides After Mixed Earnings and Tariff ConcernsCelsius Stock Surges After Blowout Earnings and Pepsi DealWhy DocuSign Could Be a SaaS Value Play After Q2 EarningsWhy Broadcom's Q3 Earnings Were a Huge Win for AVGO BullsAffirm Crushes Earnings Expectations, Turns Bears into BelieversAmbarella's Earnings Prove Its Edge AI Strategy Is a Winner Upcoming Earnings FedEx (9/18/2025)Micron Technology (9/23/2025)AutoZone (9/23/2025)Cintas (9/24/2025)Costco Wholesale (9/25/2025)Accenture (9/25/2025)NIKE (9/30/2025)PepsiCo (10/9/2025)BlackRock (10/10/2025)Fastenal (10/13/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
